期刊文献+

副肿瘤性周围神经病18例临床特点分析

Clinical features analysis of 18 cases of paraneoplastic peripheral neuropathy
原文传递
导出
摘要 目的:探讨副肿瘤性周围神经病(PPN)的临床特点。方法回顾性总结分析2005年3月至2015年8月收治的18例 PPN 患者的临床资料。结果本研究患者发病年龄为(48.9±18.0)岁,男13例,女5例。5.6%的患者在发现肿瘤后才出现周围神经病症状,94.4%在出现周围神经症状后才发现肿瘤。诊断出 PPN 时,33.3%肿瘤已出现转移。从出现周围神经病症状至发现肿瘤时间为(16±7)个月,患者多为慢性隐袭或亚急性起病,症状进行性加重。结论 PPN 的临床症状可发生在肿瘤发现之前、之后或与之同时发生,PPN 的出现预示预后差。临床早期诊断对于及时发现和治疗癌肿至关重要。 Objective To investigate the clinical characteristics of paraneoplastic peripheral neuropathy(PPN). Methods The clinical data of 18 patients with PPN from March 2005 to Augest 2013 were retrospectively analyzed. Results The age of onset in the group was(48. 9 ± 18. 0)years old,13 male and 5 female. 5. 6% of the patients had symptoms of peripheral neuropathy after found the tumor,94. 4% found the tumor after the peripheral nervous symptoms appeared. When the PPN was found,33. 3% of the tumor metastasis had been transferred. From the onset of peripheral neuropathy symptoms to find the tumor,the time was(16 ± 7)months. The onset of the disease was chronic insidi-ous or subacute and the symptoms were progressive. Conclusions The clinical symptoms of PPN may occur in the tumor before,after or at the same time,the occurrence of PPN indicates a poor prognosis. The early clinical diagnosis for timely detection and treatment of cancer is very important.
出处 《中国实用医刊》 2016年第17期17-19,共3页 Chinese Journal of Practical Medicine
关键词 副肿瘤性周围神经病 临床表现 早期诊断 Paraneoplastic peripheral neuropath Clinical characteristics Early diagnosis
  • 相关文献

参考文献10

  • 1王湘,白春梅.神经系统副肿瘤综合征的研究进展[J].癌症进展,2011,9(1):58-62. 被引量:17
  • 2Darnell RB,Posner JB. Paraneoplastic syndromes involving the nervoussystem[J].Engl J Med,2003,349( 16) : 1543-1554.
  • 3Greenlee JE. Recommended diagnostic criteria for paraneoplastic neu-rological syndromesf J]. J Neurosurg Psychiatry ,2004,75(8) :1090.
  • 4任海涛,赵燕环,关鸿志,李晓光,邵宇权,陈建华,陈琳.抗Hu抗体检测在神经系统副肿瘤综合征诊断中的临床意义[J].中国神经免疫学和神经病学杂志,2011,18(5):332-335. 被引量:36
  • 5Kuntzer T,Antoine JC,Steck AJ. Clinical features and pathophysiolog-ical basis of sensory neuronopathies ( ganglionopathies) [ J]. MuscleNerve,2004,30(3) :255-268.
  • 6陈健华,李晓光.抗神经抗体的研究进展[J].中华神经科杂志,2010,43(4):298-301. 被引量:6
  • 7陈健华,李晓光,陈琳,宋杨,崔丽英.头晕、头痛、双眼视力下降[J].中国现代神经疾病杂志,2009,9(5):514-517. 被引量:2
  • 8Basu S,Alavi A. Role of FDG-PET in the clinical managemeng of pa-raneoplastic neurological syndrome : detection of the underlying malig-nancy and the brain PET-MRI correlates [ J ]. Mollmaging Biol, 2008,10(3) :131-137.
  • 9Chrissa S,Andreas F,Athanassios P. Paraneoplastic neurological syn-dromes and the role of PET imaging [ J ] . Oncology,2010,78 ( 2 ):150-156.
  • 10Greenlee JE, Clawson SA, Hill KE, et al. Antineuronal autoantibod-ies in paraneoplastic cerebellar degeneration asciated with adenocarci-nama of the prostate[ J]. J Neurolo Sci,2010,291 ( 1-2) :74-78.

二级参考文献88

  • 1Toribio- Garcia JA, Franco- Benito M, Garcia- Ruiz- de- Morales JM. Paraneopalstic optic neuritis in an unknown small cell lung carcinoma defined by CRMP-5-IgG. Arch Soc Esp Oftalmol, 2007, 82:777-780.
  • 2de la Sayette V, Bertran F, Honnorat J, et al. Paraneoplastic cerebellar syndrome and optic neuritis with anti - CV2 antibodies: clinical response to excision of the primary tumor. Arch Neurol, 1998, 55:405-408.
  • 3Antoine JC, Honnorat J, Vocanson C, et al. Posterior uveitis, paraneoplastic encephalomyelitis and auto- antibodies reacting with developmental protein of brain and retina. J Neurol Sci, 1993, 117(1/2):215-223.
  • 4Stich O, Rauer S. Antigen- specific oligoclonal bands in cerebrospinal fluid and serum from patients with anti - amphiphysin- and anti- CV2/CRMP5 associated paraneoplastic neurological syndromes. Eur J Neurol, 2007, 14:650-653.
  • 5Monstad SE, Drivsholm L, Skeie GO, et al. CRMP5 antibodies in patients with small- cell lung cancer or thymoma. Cancer hnmunol Immunother, 2008, 57:227-232.
  • 6Camdessnche JP, Lassabliere F, Meyronnet D, et al. Expression of the onconeural CV2/CRMP5 antigen in thymus and thymoma. J Neuroimmunol, 2006, 174(1/2):168-173.
  • 7Honnorat J, Cartalat-Carel S, Ricard D, et al. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry, 2009, 80:412-416.
  • 8Baehring JM. Paraneoplastic syndromes//Goetz CG. Textbook of clinical neurology. 3rd ed. Philadelphis, PA: Saunders, 2007:1041-1058.
  • 9Mehta SH, Morgan JC, Sethi KD. Paraneoplastic movement disorders. Curr Neurol Neurosci Rep, 2009, 9:285-291.
  • 10Toothaker TB, Rubin M. Paraneoplastic neurological syndromes: a review. Neurologist, 2009, 15:21-33.

共引文献55

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部